drugset / Trial / NCT04312568
Evaluate Safety, Tolerability and Pharmacokinetics of Fadanafil （XZP-5849）in Chinese Healthy Adult Male Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety , tolerability, and pharmacokinetics of ascending single dose Fadanafil （XZP-5849）in Chinese healthy adult male subjects. This is the first XZP-5849 clinical study
Timeline
- Start
- 2018-08-10
- Primary completion
- 2018-12-07
- Completion
- 2018-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fadanafil | Unknown | 12.5 mg | — |
| Subject | Fadanafil | Unknown | 25 mg | — |
| Subject | Fadanafil | Unknown | 50 mg | — |
| Subject | Fadanafil | Unknown | 100 mg | — |
| Subject | Fadanafil | Unknown | 200 mg | — |
| Subject | Fadanafil | Unknown | 300 mg | — |
| Subject | Fadanafil | Unknown | 400 mg | — |
| Subject | Fadanafil | Unknown | 500 mg | — |
Indications
No indication recorded.